The present application relates to bridged triarylamines conforming to a defined formula. These compounds are suitable for use in electronic devices. The present application further relates to processes for preparing the compounds, and to electronic devices comprising the compounds.

The present application relates to bridged triarylamines conforming to a defined formula. These compounds are suitable for use in electronic devices. The present application further relates to processes for preparing the compounds, and to electronic devices comprising the compounds.

Disclosed are a compound as shown in formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor.

##STR00001##

Compounds having the formula I wherein R.sup.1, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. ##STR00001##

Compounds having the formula I wherein R.sup.1, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. ##STR00001##

The present invention relates to condensed N-heteroaromatic compounds, to processes for preparing these compounds, and to electronic devices containing said compounds.

The invention discloses a monosubstituted or polysubstituted amphiphilic hypocrellin derivative, and a preparation method and application thereof. The amphiphilic hypocrellin derivative substituted by a group containing PEG, a quaternary ammonium salt or the like prepared according to the invention has an obvious red shift in its absorption spectrum and a significantly enhanced molar extinction coefficient, compared with the parent hypocrellin, can efficiently produce singlet state oxygen and other reactive oxygen species under photosensitive conditions; has different amphiphilicities and increased biocompatibility with cells or tissues by regulating its hydrophilicity and hydrophobicity; can meet the requirements of different clinical drugs, and solves the requirements of different drug delivery methods for different drug hydrophilicity and lipophilicity. Under identical conditions, the amphiphilic hypocrellin derivative photosensitizer according to the invention has higher ability to photodynamically inactivate tumor cells than the first and second generation commercial photosensitizers.

The invention discloses a monosubstituted or polysubstituted amphiphilic hypocrellin derivative, and a preparation method and application thereof. The amphiphilic hypocrellin derivative substituted by a group containing PEG, a quaternary ammonium salt or the like prepared according to the invention has an obvious red shift in its absorption spectrum and a significantly enhanced molar extinction coefficient, compared with the parent hypocrellin, can efficiently produce singlet state oxygen and other reactive oxygen species under photosensitive conditions; has different amphiphilicities and increased biocompatibility with cells or tissues by regulating its hydrophilicity and hydrophobicity; can meet the requirements of different clinical drugs, and solves the requirements of different drug delivery methods for different drug hydrophilicity and lipophilicity. Under identical conditions, the amphiphilic hypocrellin derivative photosensitizer according to the invention has higher ability to photodynamically inactivate tumor cells than the first and second generation commercial photosensitizers.

Disclosed are an oxazine compound and an application thereof. The oxazine compound has a structure of a general formula F. The oxazine compound described in the disclosure is a photo/acoustic dynamic active organic molecule with near-infrared absorption-emission function as well as photosensitivity and acoustic sensitivity. Maximum absorption and emission wavelengths of the compound are both greater than 660 nanometers, and a triplet-state conversion rate of the compound is high; and under illumination or ultrasound, the compound can produce reactive oxygen species with high efficiency, which has a good killing effect on cancer cells and cancer tissues, and almost has no toxic or side effects on normal tissues while achieving photo/acoustic dynamic therapy on tumors.

Disclosed are an oxazine compound and an application thereof. The oxazine compound has a structure of a general formula F. The oxazine compound described in the disclosure is a photo/acoustic dynamic active organic molecule with near-infrared absorption-emission function as well as photosensitivity and acoustic sensitivity. Maximum absorption and emission wavelengths of the compound are both greater than 660 nanometers, and a triplet-state conversion rate of the compound is high; and under illumination or ultrasound, the compound can produce reactive oxygen species with high efficiency, which has a good killing effect on cancer cells and cancer tissues, and almost has no toxic or side effects on normal tissues while achieving photo/acoustic dynamic therapy on tumors.